Sun Pharma’s Baska Plant Gets OAI Classification from USFDA; Company to Work on Compliance

India’s largest drugmaker Sun Pharmaceutical Industries Ltd has announced that the USFDA has issued an Official Action Indicated (OAI) status for its Baska facility in Gujarat after a recent inspection. This classification means that certain regulatory or quality system deficiencies were observed that require corrective action by the company.

Despite the OAI status, Sun Pharma emphasized that the development will not disrupt supply of its currently approved products to the US market. The company affirmed its commitment to working closely with the USFDA to address all observations and bring the site into full regulatory compliance.

Key Highlights:

Facility: Baska manufacturing plant, Gujarat.

Regulatory Status: Classified as OAI (Official Action Indicated) by USFDA.

Implication: Indicates need for corrective measures before new approvals.

Operations: Production and supply of approved products to the US will continue.

Next Steps: Sun Pharma to engage with USFDA for compliance resolution.

Source: Company statement; regulatory filing with stock exchanges.